Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2012 Feb;109(7):115-6.
doi: 10.3238/arztebl.2012.0115. Epub 2012 Feb 17.

The dilemma between efficacy as defined by regulatory bodies and effectiveness in clinical practice

Gerd Glaeske
Editorial

The dilemma between efficacy as defined by regulatory bodies and effectiveness in clinical practice

Gerd Glaeske. Dtsch Arztebl Int. 2012 Feb.
No abstract available

PubMed Disclaimer

References

    1. Ujeyl M, Schlegel C, Walter S, Guntert-Remy U. New drugs: evidence relating to their therapeutic value after introduction to the market. Dtsch Arztebl Int. 2012;109(7):117–123. DOI: 10.3238/arztebl.2012.0117. - PMC - PubMed
    1. Eichler HG, Pignatti F, Flamion B, Leufkens H, Breckenridge A. Balancing early market access to new drugs with the need for benefit/risk data: mounting dilemma. Nat Rev Drug Discov. 2008;7:818–826. - PubMed
    1. Eichler HG, Bloechl-Daum B, Abadie E, Barnett D, König F, Pearson S. Relative efficacy: an emerging issue between regulatory agencies and third-party payers. Nat Rev Drug Discov. 2010;9:277–291. - PubMed
    1. Glaeske G, Höffken K, Ludwig WD, Schrappe M, Weißbach L, Wille E. Sicherstellung einer effizienten Arzneimittelversorgung in der Onkologie. Gutachten im Auftrag des Bundesministeriums für Gesundheit Bremen. 2010 Aug
    1. Ludwig WD. Kostenzuwächse bei neuen Wirkstoffen am Beispiel der Onkologie: Welche Ergebnisse benötigen wir zu patientenrelevanten Endpunkten aus klinischen Studien? Gesundheitsökonomie Report 1. 2009;1:37–42.

Publication types